Table 1.

Age* (years)	Duration of Disease* (years)	Gender	Stimulation Site	Recording Site	Stimulator Settings	Medications
70	30	M	L STN	R STN	3+, 1−, 3.0 V, 60 μs, 160 Hz	carbidopa/levodopa, trihexyphenidyl, gabapentin
40	10	M	R STN	L STN	Case +, 3−, 3.3 V, 90 μs, 160 Hz	carbidopa/levodopa, entacapone, quetiapine, alprazolam
70	20	M	L STN	R STN	Case +, 2−, 3.8 V, 90 μs, 160 Hz	carbidopa/levodopa, entacapone, ropinirole, quetiapine
70	20	F	R STN	L STN	Case +, 3−, 2.5 V, 60 μs, 145 Hz	carbidopa/levodopa, trihexyphenidyl, alprazolam
70	20	F	L STN	R STN	Case +, 0−, 3.3 V, 90 μs, 160 Hz	caribdopa/levodopa, alprazolam, gabapentin
60	20	F	R STN	L STN	3+, 0−, 3.3 V, 60 μs, 160 Hz	carbidopa/levodopa, ropinirole
60	30	M	R STN	L STN	3+, 1−, 3.3 V, 60 μs, 160 Hz	carbidopa/levodopa, entacapone, propranolol
50	10	M	L STN	R STN	Case +, 1−, 1.7 V, 90 μs, 185 Hz	carbidopa/levodopa, ropinirole
61.1 ± 10.9†	18.3 ± 7.7†	M (0.63)	L (0.5)	L (0.5)

STN, subthalamic nucleus.

^*Rounded to nearest decade;

^†means ± SD.